New combo therapy shows promise for rare liposarcoma

This phase 2 study tested whether adding pioglitazone (a diabetes drug) to trabectedin (a chemotherapy) could help shrink or control liposarcoma, a rare cancer of fat tissue. The study included 10 patients whose tumors had stopped growing but not shrunk with trabectedin alone. Researchers measured tumor response and side effects to see if the combination was safe and effective.